Depression and Anxiety Trial, Recruiting NCT04783103 Sponsor: Universitair Ziekenhuis Brussel Condition: Depression and Anxiety
Back to Depression And Anxiety

Depression and Anxiety Trial, Recruiting

NCT04783103
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 65 years or older, whether they are currently in hospital or being treated as outpatients.
  • People who have been diagnosed with unipolar depression (a form of depression without manic episodes) based on standard diagnostic guidelines, with a depression severity score of 17 or higher on a recognised rating scale called the HDRS-17.
  • People whose depression has not improved after trying at least one full course of antidepressant medication, including the one they are currently taking.
  • People who plan to continue their current antidepressant medication (which they have been taking for more than 6 weeks) at the same dose throughout the study period.
  • People who take benzodiazepines (a type of calming or anxiety medication) at a dose no higher than the equivalent of 40 mg of diazepam per day, with the dose having been stable for at least 2 weeks if it was recently changed.
  • People who are able to read, understand, and sign a consent form agreeing to take part in the study.

Who may not be able to join:

  • People who have a psychotic condition, except where psychosis is part of their depression (confirm with trial site).
  • People with a personal or close family history of seizures or epilepsy, any known factors that can lower the threshold for having a seizure (such as sleep deprivation or substance use), a previous head injury, or metal implants in the head area (such as aneurysm clips, shunts, brain stimulators, cochlear implants, or electrodes) — dental fillings are generally not included in this exclusion.
  • People who have a cardiac pacemaker, neurostimulator, surgical clips, or other electronic medical devices in the body, or who have certain neurological conditions such as raised pressure in the brain, a brain tumour, a history of stroke or mini-stroke, a brain aneurysm, or any structural brain damage that raises the risk of seizures as detected by MRI.
  • People with significant memory or thinking difficulties, or dementia, as measured by a standard cognitive test (a score below 24 on the Mini Mental State Examination).
  • People who have made a suicide attempt in the 6 months before the study starts, or who are currently considered by the treating doctor to be at high risk of suicide, including those who answer "yes" to a specific question about having an active plan and intent to end their life on recognised suicide assessment scales.
  • People who make any changes to their regular psychiatric medications during the study, as this would result in withdrawal from the trial.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Dieter Zeeuws, MD, Universitair Ziekenhuis Brussel

Phone: +324763459

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Universitair Ziekenhuis Brussel
Registry
ClinicalTrials.gov
Start date
7 May 2021
Est. completion
1 February 2025

Where this trial is recruiting

🇧🇪 Belgium

Primary endpoints

Clinical effect of adTMS (Changes in depression severity clinician-rated and self-report)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov